HCIF AZ Blue Bar

Why pursue an endowment model?

Access to capital has been key objective of Arizona's Bioscience Roadmap since its creation in 2002 and is one of the few items that continue to be an ongoing growth challenge for the industry.  While Arizona has explored various solutions over the years including state funding, privately managed fund of fund structures and other solutions, none have yielded  results.  Arizona continued to lag its peer group in  venture capital funding, and  Arizona’s life science employment growth percentage continues to lag its growth in the number of firms.

Unlike traditional fund models that raise funds, invest them and are completed, the HCIF model allows for a single capital campaign followed by ongoing investment for years to come.  In addition, as the base endowment grows, it provides additional  support for future industry need and growth.


Why is de-risking early stage opportunities important?

Early stage investors have many options for their investment dollars. Life science opportunities, especially those that are early in the development cycle, can appear daunting at best.

HCIF’s endowment based model allows companies access to  capital to help them progress further along the development cycle and begin to mitigate early development risk.

In addition, AZ-HCIF grants to local incubators and accelerators can help to provide access to experienced life science personnel and other business resources that help the companies to mature faster, further mitigating investment risk. As the degree of risk declines over time, the level of investment will naturally increase.


What is the impact of having a Resident Institutional Lead Investor in Arizona?

History has shown that when Arizona had institutional investment focused on the life science sector based in the state, levels of life science venture investment were significantly higher.

HCIF’s investments into Arizona life science companies, at the direction of the  AZ-HCIF trustees, can serve as a first institutional investor for local companies and  provide syndication support to additional local and out of state investment partners.

HCIF’s endowment model also provides a steady stream  of  investment capital  inside the state so that the peaks and valleys of traditional venture fund structures can be avoided.  In addition, through AZ-HCIF’s support of incubators and accelerators across  Arizona’s life science innovation ecosystem, entrepreneurs are better supported and more likely to succeed.

Image Source: Source: TEConomy Partners for the Flinn Foundation Arizona Bioscience Roadmap Update (2016)


How can this help keep  companies here?

There is always a risk that promising young firms will be drawn away or forced to move in their quest for investment dollars. Past experience has shown that the best way to keep companies in place is to root them in the community.  Companies are rooted by investments in  facilities, strategic partnerships with universities or clinical partners, or by key local talent. Past examples of well rooted companies that stayed and continue to grow here include Ventana (Roche), Abraxis (Celgene), Ulthera (Merz), CBR (AMAG Pharmaceuticals) and MicroRel (Medtronic).


What are some of the types of programs that could be supported by the AZ-HCIF?

All decisions on grants and investments made from the annual AZ-HCIF distribution will be directed by AZ-HCIF's Arizona-based Board of Trustees based on what they believe will have the greatest potential for  impact each year.


Who is leading the AZ-HCIF Capital Campaign?

A coalition of nonprofit organizations has come together to raise a $200 million endowment to support the commercialization of life changing and lifesaving healthcare innovations that are developed by Arizona-based researchers and entrepreneurs.

The founding members of the coalition include the Arizona Bioindustry Association, Inc. (AZBio) and the Opportunity Through Entrepreneurship Foundation, Inc. (OTEF), a 501c3 pubic charity based in Arizona, as well as the Healthcare Impact Foundation, a Delaware 501c3 public charity based in New York.

This is the second collaboration between OTEF and AZBio.  The first was the creation of D3Bio, a division of OTEF, which launched in 2014 to support life science innovation and life science innovators along the pathway from discovery to development to delivery.


How can I help?

There are many ways that members of our community can get involved in helping AZ-HCIF achieve the goal of building a $200 Million Endowment and $50 Million Direct Impact Fund by the end of 2019.  For ideas on how you can get involved, click here.

To request more information, please contact us.

As more questions are received, this page will be updated.

HCIF Blue Bar

Healthcare Impact Foundation (“HCIF”) was formed in 2017 as a 501c3 public charity and is dedicated to building a better private equity ecosystem for healthcare innovations and supporting the commercialization of healthcare innovations as they progress from the research laboratory to the patient.

Structured as a  portfolio of endowments, each HCIF separate account is dedicated to the community that creates it and is managed with a goal of growing the base endowment and distributing a steady and sustained stream of funding annually that can be distributed by the community's trustees into the areas of its life science ecosystem in a way that will have the greatest potential impact.

“The Stetson Family Office has spent the last 18 months meeting with emerging healthcare innovation ecosystems around the US and globally. We found that while great ideas with high impact potential were coming from emerging life science markets like Arizona, the capital streams and support ecosystems are insufficient to support efficient growth of the companies.  Too much time is wasted chasing funding.  This time needs to be focused on getting high quality healthcare innovations further along the path to commercialization so that traditional venture capital and public equity funding can take it the rest of the way.   We were honored to work with our partners here in Arizona to develop a new and sustainable funding model to address this critical need.”

--- Chuck Stetson is head of the Stetson Family Office, a third and fourth generation family office in New York, and serves as Chairman of the Healthcare Impact Foundation.


How can I be sure that my gift will benefit only AZ-HCIF's mission?

Arizona’s separate account within the Healthcare Impact Foundation (AZ-HCIF) is  designed to address our early stage funding challenge in a way that is both strategic and sustainable. Its evergreen endowment provides for a steady stream of early stage capital  in perpetuity and, by reinvesting  future returns from AZ-HCIF’s early stage   investments, has the ability to also grow the base so that the distributions can grow as the endowment grows.  The base endowment is  invested in a growth-oriented, diversified portfolio of public and private investments. AZ-HCIF’s Arizona-based trustees determine which programs and projects will have the greatest potential impact. HCIF will make the distributions to the approved projects.  In the case of grants, the local trustees will administer and track performance.  In the case of early stage investments, they will  become part of AZ-HCIF’s portfolio inside HCIF.

The image below shows the basic process:

 


Who are the AZ-HCIF Trustees?

AZ-HCIF Trustees will be comprised of  Arizona Leaders as well as at least one HCIF Global Trustee.  The current HCIF Trustees are provided below.  Additional AZ-HCIF Trustees will be appointed as the endowment builds.

  • Russ Yelton currently serves as Chair of the AZ-HCIF  Trustees; President of Yelton Associates;  Board Member  at Pinnacle Transplant Technologies, Inc. where he previously served at CEO; Member of the Arizona Bioscience Roadmap Steering Committee; a member of the Phoenix Forward Bioscience Leadership Council; and Past-Chairman of the Board at AZBio.  A leader in Arizona's  Bioscience and Business communities,  Russ served as CEO of Pinnacle Transplant (2014-2017), is a past Board Member of the National Business Incubation Association; and is nationally recognized for his expertise in the business acceleration and incubation sector.  Russ was awarded his BS, Management from Appalachian State University and his MBA from Western Carolina University.
  • Joan Koerber-Walker and Eugene Durenard, PhD, currently represent HCIF on the AZ-HCIF Board of Trustees.  (See below for bio's.)

How will the AZ-HCIF Trustees make grant or investment decisions on the annual distributions?

Each year the the AZ-HCIF Trustees will determine the mix of available grant and investment dollars that will have the greatest potential impact.  It will be up to the then-current AZ-HCIF Trustees to establish or adjust  its grant making policies or allocations in accordance with AZ-HCIF's mission.

Grants

AZ-HCIF Trustees may approve  direct-expenditure grants to non-profit organizations consistent with HCIF's mission, the needs of local ecosystem and the terms of the applicable grant agreement.  Grants will be paid by HCIF at the direction of  the AZ-HCIF  Trustees to the grantee.

Mission Related Investments

AZ-HCIF Trustees may  direct HCIF to make investments in or lend to for-profit companies from its annual distribution that are consistent with HCIF's mission and the then-current investment criteria approved by  AZ-HCIF Trustees and the HCIF Investment Committee.  Investments or loans will be made by HCIF and managed within the AZ-HCIF separate account at HCIF.

Due diligence is an essential component of any investment strategy and can be even more complex in the life science sector.  In addition to due diligence resources that may be available via Arizona's Angel Groups, Life Science Incubators and Accelerators, or university systems, AZ-HCIF may draw on the expertise of White Hat Health Ventures LLC  which will provide shared services across the HCIF portfolio.


Is my gift to the AZ-HCIF endowment within the Healthcare Impact Foundation tax deductible?

The Healthcare Impact Foundation (HCIF) was incorporated  in the State of Delaware on May 16, 2017 as a Delaware  Nonstock Nonprofit Corporation organized under the Delaware Corporation Law.

The Healthcare Impact Foundation was granted IRS Section 501c3  public charity status n December 13, 2017.   EIN#82-3038867.

Please consult your tax advisor with questions about how your donation applies to your personal tax situation.  


Can I contribute  gifts of stocks or other securities?

Giving appreciated securities (publicly traded or closely held), bonds, or mutual fund shares is an option.  A gift of appreciated securities may qualify for a charitable tax deduction and may avoid the long-term capital gains tax on the appreciated value of the asset. Stocks or bonds held more than one year that have increased in value may qualify for a deduction equal to the full market value of the gift. With stocks or bonds worth less than the price you paid for them, the wisest course is to sell them and give the cash proceeds. The sale will establish a loss that may offset other capital gains income.   For more information, please contact us.

Please consult your tax advisor with questions about the deductibility of these gifts and how it applies to your personal tax situation.  


Who are the trustees of the Healthcare Impact Foundation at the Global Level?

The Global Trustees of the Healthcare Impact Foundation are:

  •  Chuck Stetson currently serves as Chairman of the Global Board of  Trustees of the Healthcare Impact Foundation.  Chuck is the CEO of the Stetson Family Office which was started by Chuck’s grandfather, Eugene W. Stetson, shortly after his grandfather personally led the buyout of the Coca-Cola Company through a public offering in August 1919 by the Guaranty Trust Company of New York, where he was subsequently Chairman.  At his death, he was Coca-Cola’s longest serving member of the Board and member of the Executive Committee. Chuck, who is the third generation running the family office, is an entrepreneur and venture capitalist. In addition to his role as Chairman of HCIF, Chuck currently serves as CEO of Private Equity Investors (PEI) in New York City and is a co-founder  of White Hat Health Ventures, LLC and is founder and Chairman of Essentials in Education,  a non-profit educational organization whose mission is to provide quality educational materials that are standards-based, instructionally sound, and encourage high character. Chuck was awarded his BA in Literature from Yale University and his MBA  Finance from Columbia University.
  • Eugene Durenard, PhD, currently serves as a Global Trustee of the Healthcare Impact Foundation and chair of its investment committee; Managing Director of the Stetson Family Office; and is a co-founder of White Hat Health Ventures, LLC.  Eugene brings a thorough multi-asset class investment and entrepreneurial experience spanning 20 years. Past positions include proprietary research at Salomon Brothers, proprietary trading at Credit Suisse, co-founder of Orion Investment Management, an institutional asset manager in Bermuda that Eugene sold  in 2011 to the privately owned Capital G Bank and co-managed $1.2 billion of the bank's assets.  Eugene was awarded his DEA (MSc), Mathematics from Ecole Normale Supérieure (Paris) and his PhD in Mathematics from Harvard University.
  • Chuck Bauer, currently serves as a Global Trustee of the Healthcare Impact Foundation; managing director, COO and CFO at Rowayton Real Estate Holdings LLC; and managing director and registered principal at Eastridge Capital LP. Chuck spent the majority of his professional career with PricewaterhouseCoopers LLP (PwC) serving in a variety of client and leadership roles, including as a Vice Chairman and a member of the firm's U.S. Leadership Team, and as the global audit partner for eight Fortune 500 companies. Chuck was awarded his BS, Accounting and MBA from the University of Central Missouri.
  • Joan Koerber-Walker, currently serves as a Global Trustee of the Healthcare Impact Foundation; Managing Member and co-founder, White Hat Health Ventures LLC; Chairman of the Opportunity Through  Entrepreneurship Foundation (OTEF); and President & CEO, Arizona Bioindustry Association (AZBio).  Joan's career includes past roles as CEO of the Arizona Small Business Association; as Treasurer and Board Member for RiboMed Biotechnologies, Inc.; and as an executive at Avnet, Inc, where, for over a 20 year span, she held a wide variety of roles in sales, marketing, technology, supply chain management, and global administration. She has served in the non profit community for over two decades including as a member of the Board of Trustees of the National Small Business Association in Washington D.C.; Chair of the Board of Advisors to CPLC Parenting Arizona, a child abuse prevention agency that provides family support services across Arizona; and as a member of the Executive Committee of the Industry Advisory Board for the Thomas and Joan Read Center at Texas A&M University.   Joan was awarded a BA in Economics from the University of Delaware, an MBA from the W.P. Carey School of Business at Arizona State University, and is a member of Beta Gamma Sigma.
  • Pamela Newman, PhD, currently serves as a Global Trustee of the Healthcare Impact Foundation.  Prior  to her retirement in 2017, Pamela was Chairman of The Newman Team at Aon Risk Services and served as an Executive Vice President for the firm.  She was awarded her PhD in Communications and Media Studies from The University of Michigan.
  • Damaris Skouras, currently serves as a Global Trustee of the Healthcare Impact Foundation; CEO of Olatec Therapeutics LLC, Founder and CEO, Global Reach Management Company (New York) and as a member of the board of directors of the Steadman Philippon Research Institute (Colorado) and the  Mederi Foundation (Oregon). Damaris has over 20 years of experience in pharmaceutical drug development. She began her career in finance in 1982 as a Vice President at Allen & Company Inc., where she was responsible for several biotech and technology start-up Companies from early inception through exit. Damaris  was awarded a BA from Stanford University and an MBA from Harvard University.